Murcidencel (DCVax-L) is now listed as "CANCER" on the NHS High-Cost Drugs List (HCDL), not just glioblastoma.

This change could signal broader potential for solid tumors beyond GBM. Here’s why that might be the case. 👇 2/13

Clinical Experience Across Tumors

The Czech trial under Murcidencel includes various cancers:

Brain Tumors (GBM, Astrocytoma)
Sarcomas (Ewing's, Rhabdomyo, Osteo)

Others (Neuroblastoma, Burkitt's Lymphoma)

This suggests potential multi-cancer reach.

$NWBO

1/8

Would this explain the delay?

It would!

🔥 Major Update: Murcidencel (DCVax-L) is no longer listed as just for "Glioblastoma" on the NHS High Cost Drugs List.

It's now classified simply as "Cancer". This is not just a name change-a signal of something much bigger. 2/8

💡 Why This Matters:

A shift from a specific cancer (Glioblastoma) to a broad "Cancer" label means the NHS is ready for broader patient access.

It opens doors for Individual Funding Requests (IFRs) across multiple solid tumor types.

$NWBO

Canpuldencel-t has been deleted april 1st. from NHS High Cost Drugs list.

What does this mean for NWBO? 1/11 🚀

Big news for $NWBO:

Canpuldencel-T is officially gone from the NHSPS (NHS Payment Scheme) list.

Why is this important?

Because it signals the full regulatory transition to the new INN name:

Murcidencel.

Murcidencel's NHS Listing and MHRA Approval — Are They Aligned? 1/16

Murcidencel was officially added to the NHS High

Cost Drugs List (Version 20.0 – Final, April 2025).
Indicated for cancer treatment.

Accessible via Individual Funding Requests (IFR).

Murcidencel's Global Recognition & NHS High Cost Drug List

MILESTONE 1/18

Murcidencel, the WHO-assigned INN for DCVax-L, has achieved major regulatory milestones:

Included in WHO INN Proposed List 128 (2023)

Advanced to WHO INN Recommended List 90 (2023)

Confirming global recognition for NWBO's DC vaccine.

NHS: April 1st.
NICE: April 2nd.

$NWBO

Czech Trial: The Missing Link

With the help of @d_stock07734's due diligence, it seems like we are able to uncover what must have been quite a challenge at that time for Masaryk University.

The manufactoring of the dendritic cell vaccine for the trial. Please follow @d_stock07734 for additional due diligence regarding the Czech Trial results and other possible links.

🙏

https://x.com/d_stock07734/status/1919062992500543831

$NWBO

Allow me to entertain a hypothesis, that is probable "far out", but which I somehow still find believable, knowing Linda Powers setup several dormant companies in 2014, obviously trying to predict a few chess board moves over the last decade.

Let's say she did that. 1/

Something extraordinary may have just come together for NWBO - and many missed it.

A Czech trial, once unrelated, now bears the name Murcidencel - the official WHO name for NWBO’s DCVax-L.

Coincidence?

ChatGPT and Perplexity says otherwise.

$NWBO

1/

Laura Posner (Cohen Milstein) & Columbia law prof Joshua Mitts filed a powerful amicus brief in Slack v. Pirani, arguing that modern tech makes it possible to trace stock origins—a key issue in securities fraud.

Source:

cohenmilstein.com/laura-posner-d… 2/

In the case, the Supreme Court ruled that if you sue under Section 11 of the Securities Act, you must prove your shares came from the registration statement you’re challenging.

That’s called traceability

$NWBO

1.

The Czechia 🇨🇿 trial has just been updated 20.00 local time. It’s a public holiday in many countries and after business hours in Europe,

That’s the 4th consecutive update in 4 days.

But why now, and from where? 2/

First: this is not a recruiting trial.

It ended in 2024, is marked “Not Recruiting,” and was migrated into CTIS for administrative purposes.

Yet it’s getting multiple backend updates — and the latest occurred at 8PM local time on a national holiday.

$NWBO

Read!

Best news this week. 👍🏻

$NWBO

UK Parliament Response on DCVax-L (April 28, 2025)

One of Sarah Owens’ questions has been answered.

questions-statements.parliament.uk/written-questi… 1/5

Official UK Parliament answer confirms:

•DCVax-L is not yet licensed by MHRA.

•NWBO has submitted the application and is fully engaged with MHRA.

No rejection, no pause — review ongoing.

$NWBO

1/7

If $NWBO’s DCVax-L is approved for both Grade 3 & 4 gliomas, covering newly diagnosed and recurrent GBM, it’s a major leap forward — not just a drug approval, but platform validation.

Here’s what it would mean: 2/7

Such a broad label would:

• Expand the patient population
• Boost valuation
• Open doors to pan-solid tumor use
• Strengthen NWBO’s case for NICE + EU filings

It flips the “niche drug” narrative on its head.

1/

$NWBO trading has been suspended on Börse Stuttgart since April 9.

No trades. No fix. No public explanation.

While Stuttgart is a secondary exchange, this extended halt may carry broader implications.

Here’s what we know.

Thanks to @smith348572 for due diligence 🙏🏻 2/

Börse Berlin — another German exchange — publicly warns that OTC stocks can be subject to fraudulent trading practices that occur simultaneously in the U.S. and Germany.

This highlights cross-market vulnerabilities, particularly in thinly traded securities.

$NWBO

NICE updated status on NWBO collaboration.

ChatGPT, Grok & Gemini say:

"NICE’s active appraisal of DCVax-L signals MHRA approval is imminent or already granted — unlocking the path to NHS funding, UK rollout, & real revenue.
👉 Huge validation for $NWBO & patients."

👇 ChatGPT:

💥 NWBO milestone:

NICE (UK) is appraising DCVax-L for glioblastoma (GID-TA10143).

This strongly signals MHRA approval is imminent—or already granted (but not yet announced).

It’s about routine NHS use. Here’s why:

$NWBO

$NWBO

Spoofing has continued until the ruling. Probably also naked shorting.

Would market makers be able to continue and hope this will not be revealed during discovery or would they be better of to stop?

$NWBO

I have made several AI's concurrently look into all SEC filings, PR's, ASMs and all criticism today on Investorshub into this thesis, and correlating their answers between them:

Was Flaskworks EDEN
included in the
MAA for DCVax-L?

In short? prnewswire.com/news-releases/…

$NWBO

Thanks to @voloda37814097 for this.

🚨 MY FINAL TAKE on MHRA’s MIA Update (UK MIA 54923) & DCVax-L! 🚨

MHRA shifting Advent’s MIA from “Human” to Regulation 17 (Wholesale Distribution) is a BIG SIGNAL for DCVax-L’s path to commercialization. Let’s break it down 🧵👇 1️⃣ What This Means: A Distribution Step
🔹 MHRA updated Advent’s MIA on Feb 28, 2025 from “Human” to “Regulation 17”
🔹 R 17 covers wholesale authorization → Advent may now distribute DCVax-L
🔹 Ties into MHRA’s ATMP framework & post-approval steps → Getting DCVax-L to patients

$NWBO

🚨 MY TAKE on Advent’s MIA Update
(Feb 27, 2025)! 🚨
MIA 54923 updated again in under a week—Feb 20 GMP, Feb 27 MIA.

What’s up? 🔹 Facility Upgrades Likely – I’m With ChatGPT ✅ – I think this could signal upgrades at Advent’s Sawston site, like enhancing capacity or tech (e.g., Flaskworks EDEN for DCVax-L). MHRA’s Feb 20 GMP (1-day cert) —new equipment or processes might need swift MIA updates.

$NWBO

Is the “New” Murcidencel Trial Actually an Old One? A Closer Look at the Evidence

Recently, a new clinical trial under the name Murcidencel appeared in European clinical trial databases.

🔗 Murcidencel Trial:

(1/🧵)clinicaltrials.eu Strange Detail: The Murcidencel trial has a start date of 2015 - the same period when an earlier dendritic cell vaccine (DC) trial was conducted.

The old trial, published July 2024, did not specify the vaccine’s name.

🔗 Old Trial (July 2024):

(2/🧵)onlinelibrary.wiley.com

$NWBO

Interesting take from flipper



Let's put that to a test through several AI models investorshub.advfn.com/boards/read_ms…